CXCL10 and neoplasm: A recent report revealed that treatment of hepatocellular carcinoma cells with EZH2i GSK126/343 was able to increase CXCL10 expression by tumor cells, which induced NK cell migration to the tumor site and suppressed tumor growth in a mouse model.